Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Genomics Signs on PPO MultiPlan for Coverage of Cancer Dx

NEW YORK (GenomeWeb News) – Rosetta Genomics today announced the execution of an agreement with preferred provider organization MultiPlan for Rosetta's products, including the Rosetta Cancer Origin Test.

MultiPlan has more than 900,000 healthcare providers in its network, and about 67 million Americans have access to Multiplan's network. According to Rosetta President and CEO Kenneth Berlin, his firm has executed agreements with five national US PPOs, and including Medicare, the total number of covered lives for whom the Rosetta Cancer Origin Test could be considered an in-network benefit exceeds 170 million.

Last month, Rosetta announced a deal with Highmark Health Services for coverage of the test, which is for identifying the tumor origin in cancer of unknown or uncertain primary.

"Over the past nine months we have made considerable progress executing agreements with large, national PPOs as well as with managed care organizations, thereby expanding the coverage for the Cancer Origin Test," Berlin said. "This is increasingly important as enhanced awareness of our test and the accurate identification of tumor origin in patients with metastatic cancer has resulted in record volumes of samples processed and billed at our CLIA lab over the past four months."